Celcuity

Celcuity FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Celcuity (CELC) as of Sep 26, 2026 is 86.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 74.89 % — a change of 15.79% (higher).

FCF Conversion

86.72 %

YoY

15.79%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Celcuity is 2026 86.72 % . FCF Conversion Rate (FCF/EBITDA) of Celcuity was 2025 74.89 % . It decreases by 15.79% higher compared to the previous year.

The Celcuity FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
89.64 USD
Jan 1, 2019
86.68 USD
Jan 1, 2020
76.37 USD
Jan 1, 2021
68.89 USD
Jan 1, 2022
89.59 USD
Jan 1, 2023
84.53 USD
Jan 1, 2024
74.89 USD
Jan 1, 2025
86.72 USD
The Celcuity FCF Conversion history
YEARFCF ConversionYoY
86.72 %+15.79%
74.89 %-11.39%
84.53 %-5.65%
89.59 %+30.05%
68.89 %-9.80%
76.37 %-11.90%
86.68 %-3.31%
89.64 %+8.02%
82.98 %-6.22%
88.48 %-2.75%
90.99 %—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

FCF Conversion Rate (FCF/EBITDA) of Celcuity is 86.72 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Celcuity changed from 74.89 % to 86.72 %, representing a 15.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Celcuity since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Celcuity with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Celcuity

All Key Metrics — Celcuity